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doi:10.1016/j.ejvs.2008.08.014Abstract Objective: To compare aneurysm morphology, initial outcomes and mid-term
results in patients receiving Talent or Zenith grafts for elective endovascular aneurysm repair
(EVR).
Methods: Over a 6-year time period ending in 2007, 286 patients underwent elective EVR of
infra-renal abdominal aortic aneurysms using Talent or Zenith devices. Patient demographics,
aneurysm morphology and initial outcomes (primary-assisted technical success rates, 30-day
limb occlusion, re-intervention and mortality) were compared using chi-squared tests or Stu-
dent’s t-tests. KaplaneMeier curves were calculated to compare cumulative rates of freedom
from type I or III endoleak, re-intervention, endograft patency and overall survival over mid-
term follow-up.
Results: Adverse aneurysm morphology was more common in patients receiving Zenith stent
grafts, with a greater proportion of shorter neck lengths (<10 mm, 12.9% vs 0%; p 0.001)
and severe neck angulation (>60, 25.0% vs 10.3%; pZ 0.002). Equivalent primary-assisted
technical success rates were achieved with both Talent and Zenith grafts (94.0% vs 96.1%;
pZ 0.41). A significant number of adjunctive procedures were required in both groups to
obtain a proximal endograft seal, with relatively more procedures performed in the Talent
group (28.6% vs 12.4%; pZ 0.003). Early outcomes were similar for 30-day re-intervention
(5.3% vs 3.9%; pZ 0.91), 30-day limb occlusion (1.5% vs 2.6%; pZ 0.51), 30-day morbidity
(6.8% vs 11.8%; pZ 0.15) and 30-day mortality (4.5% vs 3.9%; pZ 0.80).
The cumulative incidence of freedom from re-intervention was 88.3 2.9%, 86.1 3.3% and
84.1 3.9% at 1, 2 and 3 years respectively. There were no significant differences between
Talent and Zenith groups for re-intervention, type I or III endoleak or limb occlusion rates over
the same time period. Overall patient survival was 88.4  2.85% at 1 year, 83.7  4.0% at
2 years and 78.9 5.5% at 3 years.
Conclusions: Equivalent primary-assisted technical success rates can be achieved using either
Talent or Zenith endografts for endovascular aneurysm repair, but operating teams should be
prepared to perform additional adjunctive procedures to obtain a primary proximal seal with87253205; fax: þ442087253495.
es.nhs.uk (I. Loftus).
ty for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
662 L. Wales et al.either stent. The Zenith endograft performed well in the context of less favourable pre-oper-
ative aneurysm morphology. Both Talent and Zenith endografts appeared equally durable in
the medium term.
ª 2008 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Table 1 Endovascular devices used
Year Talent (%) Zenith (%)
2001e2002 5 (83.3) 1 (16.7)
2003 18 (51.4) 17 (48.6)
2004 30 (62.5) 18 (37.5)
2005 47 (50.0) 47 (50.0)
2006e2007 33 (32.0) 70 (68.0)Introduction
Techniques of endovascular aortic aneurysm repair (EVR)
have now become well established. Although early prob-
lems with commercial endografts resulted in several
devices being withdrawn from the market, technology for
currently used stent grafts is now relatively stable with
improved outcomes.1,2 To date, major randomised trials for
EVR have primarily focused on comparing outcomes of EVR
with open repair,3,4 and there are no randomised trials
comparing current devices for superiority of performance.
A single-centre comparative analysis of device-specific
outcomes in Ancure, AneuRx, Excluder, Talent and Zenith
devices was recently published by Ouriel et al.5 Although
overall survival was found to be diminished in the Zenith
group, there were no significant differences in aneurysm-
related death, type I or III endoleak or re-intervention
rates. However, there did appear to be significant differ-
ences in frequency of limb occlusion and endoleak of any
type between groups, with limb occlusion occurring most
frequently with the Ancure device (11 4.6% at 12 months;
pZ 0.009) and endoleak of any type with the Excluder
devices (64 11% at 12 months; pZ 0.003).
The majority of infra-renal endovascular aneurysm
repairs in Europe are performed using either the Zenith
endograft (Cook Inc., Bloomington, IN, USA) or the Talent
device (Medtronic, USA).2,3,6 A comparison of these
endografts was recently published in a post hoc analysis of
data acquired through the UK EVAR trials.6 Secondary
intervention rate, aneurysm-related mortality and all-
cause mortality for EVAR patients receiving Zenith or Talent
endografts were investigated. No difference was found in
the performance of either stent, but the perceived trend of
results for endoleak and secondary intervention appeared
to slightly favour patients with Zenith (vs Talent)
endografts.
Although morphologic characteristics of the proximal
aortic neck and size of the underlying aneurysm are known
to influence the effectiveness of aneurysm exclusion and
the durability of endograft attachment,7,8 comparative
studies of device-specific outcomes to date have reported
little information regarding initial aneurysm morphology.
The aim of this study was to compare aneurysm
morphology, initial outcome and mid-term results in
patients receiving Talent or Zenith grafts for elective
endovascular aneurysm repair (EVR).
Methods
Consecutive patients (nZ 310) undergoing EVR at the St.
George’s Vascular Institute for infra-renal abdominal
aneurysm, over a six-year period ending January 2007, were
included in the study. During this time period, 24 EVRs were
performed on patients for ruptured aneurysm or withsparsely used devices. These cases were excluded from
further analyses, enabling a direct comparison between
performances of Zenith (nZ 153) and Talent (nZ 133)
endografts, under similar clinical circumstances. Numbers
of procedures performed per year steadily increased, as did
the ratio of Zenith to Talent devices implanted (Table 1).
Device selection was performed using a multi-disciplinary
process on an individual patient basis, with consensus
opinion between vascular surgeons and radiologists.
Endografts in both device groups were used outside their
instructions for use (neck length >15 mm; angulation <60)
in several patients. Zenith devices were selected for all
patients with very short aneurysm neck lengths (<10 mm),
and preferentially for patients with severely angulated
aneurysm necks (>60).
Devices were compared using information obtained from
a prospective database, used to record patient demo-
graphics, co-morbidities, aneurysm morphology, endograft
details, operative outcomes, morbidity and mortality rates,
and patient follow-up.
Aneurysm neck morphology was categorized by senior
radiologists, reporting pre-operative computed tomography
(CT), according to a recommended grading system for
definition and categorisation of initial morphological
aneurysm status.9 Anatomical characteristics measured
included neck length (>25 mm, 15e25 mm, 10e15 mm and
<10 mm), diameter (<24 mm, 24e26 mm, 26e28 mm and
>28 mm), angulation (<30, 30e45, 45e60 and <60)
and overall aneurysm size (<55 mm, 55e65 mm, 65e75 mm
and >75 mm). Expert radiological opinion was used to
decide upon suitability of iliac artery morphology for access
purposes, with a global evaluation of adequate diameter
(>7 mm), patency, tortuosity and extent of calcification. If
iliac artery morphology was considered potentially inade-
quate for device delivery on the basis of CT findings, pre-
operative diagnostic arteriography was performed. All
patients underwent duplex and CT imaging prior to
discharge, except those patients with significant renal
insufficiency, where duplex scanning showed no evidence
of type I or III endoleak. In these patients, CT scanning was
delayed to six weeks post-operatively, and performed with
a reno-protective regime of intravenous hydration
combined with oral N-acetylcysteine. Further duplex
imaging was obtained following discharge at six weeks,
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combination with clinical history and examination.
Initial outcome measures of operative outcome included
primary-assisted technical success rates, 30-day re-inter-
vention, limb occlusion, and morbidity and mortality rates.
Initial and ongoing rates of endoleak, re-intervention, limb
occlusion and patient survival were compared to mid-term
follow-up.
Reporting of all operative outcomes was based on rec-
ommended reporting standards for endovascular aneurysm
repair.10 Primary-assisted technical success was defined as
the successful introduction and deployment of the device in
the absence of surgical conversion, mortality, type I or III
endoleak, limb occlusion, with or without unplanned
adjunctive procedures. Type I endoleak was defined as peri-
graft blood flow caused by inadequate seal at either the
proximal or distal graft ends. An endoleak caused by fabric
disruption or component disconnection was classified as
a type III endoleak. Conversion from endovascular to open
repair was defined as primary if required at the original
operation or secondary if performed on a subsequent
occasion.
Deaths and morbidity occurring within 30 days of the
operative procedure were considered procedure related.
Deaths occurring after 30 days were defined as late deaths.
Aneurysm-related deaths were defined as all deaths due to
aneurysm rupture, a primary or secondary procedure, or
surgical conversion. Causes of death were classified as
verified (autopsy) or probable (consistent with reliable
observation during the terminal illness). When these
criteria could not be met, the cause of death was classified
as indeterminate.10
Definitions for significant in-patient morbidity were
based on standards published by the Ad Hoc Committee for
Standardized Reporting Practices in Vascular Surgery of the
Society for Vascular Surgery/American Association for
Vascular Surgery.10 Minimum inclusion criteria for signifi-
cant (moderate to severe) systemic complications included
cardiac (symptomatic requiring medical intervention),
renal insufficiency (prolonged hospitalisation or dialysis),
cerebrovascular (delayed recovery or CT confirmed cere-
brovascular event), deep vein thrombosis (requiring
medical intervention), pulmonary embolus (requiring
medical intervention), coagulopathy (requiring transfusion
therapy), bowel ischaemia (requiring intervention), gastro-
intestinal bleed (requiring endoscopic or surgical inter-
vention), severe sepsis (documented infection with new
organ dysfunction) and spinal cord ischaemia (delayed
recovery or permanent deficit). Patient morbidity due to
access site complications (haematoma, infection, false
aneurysm or lymphocele requiring evacuation, debride-
ment, repair or open drainage) and post-operative periph-
eral arterial complications requiring further intervention
were also included.10Statistical analysis
Comparative analyses of patient demographics and initial
outcomes were performed using chi-square or Student’s
t-tests as appropriate. Ongoing risks for endoleak, re-
intervention, limb occlusion and survival were defined inbinary fashion for each type of endograft. Binary outcome
events were analysed over the observed mid-term follow-
up period using the KaplaneMeier method.Results
During the 6-year time period, 286 patients underwent
elective EVR for infra-renal aortic aneurysm using Talent
(nZ 133) or Zenith (nZ 153) devices, ranging in age from
43 to 89 years. Patient demographics, co-morbidities and
initial operative outcomes are summarised in Table 2. Early
morbidity and mortality rates were similar between device
groups. Twelve patients (4.2%) died within 30 days of the
initial procedure, including one patient due to aneurysm
rupture and one patient due to retroperitoneal haemor-
rhage, both in the Talent group. Twenty-seven patients
(9.2%) developed one or more significant procedure-related
morbidities. Causes of 30-day morbidity and mortality are
presented in Table 3.
Median length of follow-up was 16 months (range, 0e70
months). No patients required primary or secondary
conversion to open repair during the course of the study
and there were no device failures. Late mortality rates
were similar between device groups. Out of twenty-eight
late deaths during the study follow-up period, one known
aneurysm-related death occurred in a patient receiving
a Zenith endograft, who suffered an aneurysm rupture at
two years following the primary procedure. Other causes
for late death were pneumonia (8), myocardial infarction
(4), malignancy (3), mesenteric ischaemia (1) and
indeterminate (11).
Initial operative outcomes
Equivalent primary-assisted technical success rates were
achieved in both Talent and Zenith groups (94.0% vs 96.1%;
pZ 0.41). Significantly more patients in the Talent group
required primary adjunctive procedures to obtain a prox-
imal seal (28.6% vs 12.4%; pZ 0.003). Palmaz stent
deployments were more common in the Talent group (21/
133 vs 14/153; pZ 0.005), but the numbers of patients
requiring an aortic cuff extension were similar in both
groups (10/133 vs 5/153; pZ 0.11).
Early outcomes were similar between Talent and Zenith
groups for 30-day re-intervention (5.3% vs 3.9%; pZ 0.91),
30-day limb occlusion (1.5% vs 2.6%; pZ 0.51), 30-day
morbidity (6.8% vs 11.8%; pZ 0.15) and 30-day mortality
(4.5% vs 3.9%; pZ 0.80).
Aneurysm morphology
Mean pre-operative aneurysm morphological diameters
were similar between Talent and Zenith device groups, at
61.5 mm vs 62.7 mm; pZ 0.39. After categorisation
according to aneurysm morphological status, patients
receiving Zenith stent grafts had a significantly greater
proportion of aneurysms with adverse neck morphology,
including shorter neck lengths (<10 mm, 12.9% vs 0%;
p< 0.001) and severe neck angulation (>60, 25.0% vs
10.3%; pZ 0.002) (Fig. 1).
Table 2 Patient demographics and early outcomes
Demographics Patient number (%) p-Value
Talent (nZ 133) Zenith (nZ 153)
Age 73.2 (7.44)a 73.5 (8.3)a 0.86
Male 119 (89.5) 139 (90.8) 0.71
Smoker 107 (80.5) 127 (83.0) 0.58
Diabetes 20 (15.0) 15 (9.8) 0.18
Hypertension 99 (74.4) 96 (62.7) 0.03
Hypercholesterolaemia 74 (55.6) 97 (63.4) 0.18
Coronary artery disease 62 (46.6) 75 (49.0) 0.68
Cerebrovascular disease 17 (12.8) 22 (14.4) 0.69
Chronic obstructive pulmonary disease 33 (24.8) 33 (21.6) 0.52
Renal failure 26 (19.5) 24 (15.7) 0.39
General anaesthesia 116 (87.2) 139 (90.8) 0.33
V-POSSUM 20.8 (5.4)a 20.7 (4.72)a 0.98
GAS 80.7 (10.4)a 82.7 (11.3)a 0.21
mCPI 1.82 (11.2)a 3.68 (11.5)a 0.21
CPI 1.84 (11.1)a 3.63 (11.5)a 0.16
Primary-assisted technical success 125 (94.0) 147 (96.1) 0.41
Proximal adjunctive procedures 38 (28.6) 19 (12.4) 0.003
30-day re-intervention 7 (5.3) 6 (3.9) 0.91
30-day limb occlusion 2 (1.5) 4 (2.6) 0.51
30-day mortality 6 (4.5) 6 (3.9) 0.80
30-day morbidity 9 (6.8) 18 (11.8) 0.15
V-POSSUM, Vascular Physiology and Operative Severity Score for the enUmeration of Mortality and Morbidity; GAS, Glasgow Aneurysm
Score; mCPI, modified customised probability index; CPI, customised probability index.
a Mean (SD).
664 L. Wales et al.In patients with severely angulated necks (>60), 15
patients received a Talent endograft and 36 patients
received a Zenith stent. The mean degree of angulation was
greater in the Zenith group (76.1 16.5 vs 67.5 6.7;
pZ 0.03). Of these patients, eight (53%) receiving a Talent
device developed a type I endoleak, compared to seven
patients (19%) in the Zenith group (pZ 0.0005). Eighteen
patients in the Zenith group received a Zenith endograft inTable 3 Patient morbidity and mortality
Patient number
Morbidity
Myocardial infarction 5
Pneumonia 6
Renal impairment 7
Sepsis 2
Peripheral arterial 7
Wound debridement/drainage 3
Gastro-intestinal haemorrhage 1
Mortality
Aneurysm rupture 1
Gastro-intestinal bleed 1
Ischaemic bowel 1
Myocardial infarction 3
Multi-organ failure 2
Pneumonia 3
Retroperitoneal haemorrhage 1the context of an extremely short aneurysm neck
(<10 mm), with a mean neck length of 7.2 1.9 mm. Of
these patients, seven (38.9%) developed type I endoleaks.
Mid-term results
The overall cumulative incidence of patients remaining free
from type I or III endoleak was 93.5 2.2% at 1 year,
90.2 3.0% at 2 years and 85.1 5.2% at three years, with
similar results for each device group (Fig. 2). The corre-
sponding cumulative results for patients remaining free
from re-intervention over the same time period were
88.3 2.9%, 86.1 3.3% and 84.1 3.9%. There were no
significant differences between Talent and Zenith device
groups for rates of re-intervention and limb occlusions over
36-month follow-up (Figs. 3 and 4). Overall patient survival
was 88.4 2.85% at 1 year, 83.7 4.0% at 2 years and
78.9 5.5% at 3 years. Both Zenith and Talent device
patient groups had similar survival rates (Fig. 5).
Discussion
Modern endograft design has improved the results of
endovascular aneurysm repair, but little data is available
for comparison of device-specific outcomes to date.
Although significant differences may exist between stent
grafts of differing designs, current reported data would
suggest that each stent graft has its drawbacks, and no
single device can be regarded as ideal in all cases. This
study provides a single-centre comparison of stent-graft
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Figure 1 Comparison of aneurysm morphology in Talent and
Zenith patient groups.
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Figure 2 Freedom from type I or III endoleak over mid-term
follow-up.
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absence of randomisation, caution must be applied to the
interpretation of results.
Zenith grafts were preferentially used for angulated or
short aneurysm necks in this study. The Zenith device
incorporates a bare proximal stent with 10 barbs for supra-
renal fixation, whereas the fixation of Talent stents relies
on radial force. In experimental studies on human
cadavers, proximal fixation has been shown to be very
secure with barbs, with the mean displacement force
required to displace a Zenith endograft five times greater
than that for Talent stents, at 24 N (23e26.5) vs 4.5 N (1.3e
5.5) respectively.10 However, it must be acknowledged that
both Talent and Zenith grafts were used outside their
instructions for use on several occasions in aneurysm
morphology that they were not designed for.
Current reporting standards for endovascular repair
recommend limited pre-operative classification criteria for
aneurysms according to site, aetiology and clinicopatho-
logic manifestations on the basis that over-classification
can result in small patient subgroups that preclude mean-
ingful data analysis. However, precise morphological cate-
gorisation is an essential inclusion in studies comparing
device performance, as aneurysm diameter, proximal
aortic neck diameter, infra-renal neck length and severeZenith
Talent
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Figure 3 Freedom from re-intervention over mid-term
follow-up.
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Figure 4 Freedom from limb occlusion over mid-term
follow-up.
666 L. Wales et al.neck angulation are all known to significantly affect
outcome following endovascular aneurysm repair.11e13 In
device-specific results from the UK EVAR trials, mean
morphological characteristics of aneurysm size, neck
diameter and neck length were reported, but not neck
angulation.5 Using mean values to represent morphological
aneurysm characteristics can be misleading, as the
numbers of patients with adverse anatomical characteris-
tics are not precisely defined. The numbers of procedures
performed on aneurysms with short necks (<10 mm) or
severe angulation (>60) may be more relevant in terms of
interpreting device-specific outcomes.
The main factor affecting primary technical success in
this study appeared to be adequate sealing at the proximal
anchor zone. Our unit follows an aggressive protocol for the
on-table assessment and management of type I endoleaks,
which could explain why a significant number of patients in
both groups required proximal adjunctive procedures to
obtain a primary seal. All patients receive routine balloon
dilatation at anchor zones followed by arteriography. For
type I proximal endoleaks without graft malposition during
stent deployment, a giant Palmaz stent dilated to 2 atm is
used to encourage stent apposition to the proximal neck.
However, if an endoleak appears to be due to graft migra-
tion during deployment, the graft is extended by usingZenith
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Figure 5 Patient survival over mid-term follow-up.a proximal aortic cuff, generally oversized to prevent
further endoleaks. Although patients with Talent devices
required a greater number of proximal additional endo-
vascular interventions, there were no observed differences
in mid-term outcomes for either device groups. Similar
findings are reported from the EUROSTAR registry, where
the use of proximal aortic cuffs in 259 out of 6668 patients
requiring EVR procedures did not influence outcome of
endoleak of any type at 4 years.14
There were no significant differences in device perfor-
mances over mid-term follow-up, with similar rates of type
I or III endoleak, re-intervention, limb occlusion and overall
survival. Although apparently lower cumulative incidences
of secondary intervention were recently reported in 2846
patients on the EUROSTAR registry, at 6.0%, 8.7% and 12% at
1, 2 and 3 years respectively, the report excluded all re-
interventions occurring within one month following the
index endovascular procedure.15 Our mid-term results
included an initial 30-day re-intervention rate of 5%. Once
this is taken into account, overall re-intervention rates in
this study are entirely consistent with the EUROSTAR
data.16
Overall patient survival has previously been reported to
be diminished when using Zenith stents in a single-centre
series assessing the performance of five devices (Ancure,
AneuRx, Excluder, Talent and Zenith) in 703 patients
undergoing EVR for infra-renal abdominal aneurysm repair.4
Conversely, in the EVAR trials, the trend in all-cause
mortality appeared to be greater in Talent stents.5 Our
study found no significant differences in all-cause mortality
between device groups. Overall all-cause mortality in this
study was 21% at three years, compared to 28% at four years
in the EVAR I trial.2
In summary, this study suggests equivalent primary-
assisted technical success rates can be achieved with both
Zenith and Talent stents for endovascular infra-renal
aneurysm repair. The Zenith stent performed well in the
context of less favourable aneurysm morphology. Both
stents required a significant number of proximal adjunctive
procedures and operating teams should be adequately
prepared for management of on-table proximal type I
endoleaks. Talent and Zenith stents performed equally well
in the medium term. Constant refinement and redesign of
current endografts are likely to make adequately powered
randomised trials unlikely to compare different stent
designs, but device performance should be reported with
adequate details of aneurysm morphology.
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